Trials / Recruiting
RecruitingNCT06046248
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
Phase II Trial of Belumosudil and Rituximab for the Primary Treatment of Extensive Chronic Graft-versus-host Disease
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Northside Hospital, Inc. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Belumosudil | 200mg PO QD x 24 cycles (28-day cycle) |
| DRUG | Rituximab | 375mg/m2 IV Q1 week x 4 weeks, then Q3 months x4 doses |
Timeline
- Start date
- 2024-01-29
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
- First posted
- 2023-09-21
- Last updated
- 2025-10-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06046248. Inclusion in this directory is not an endorsement.